ERBB2 and breast carcinoma: HER2-overexpressing epithelial cells in the bone marrow were found to predict poor clinical outcomes of breast cancer patients with/without distant metastasis at diagnosis (31–33); however, the consensus of the prognostic impact of HER2+ CTC in peripheral blood was still yet to be studied (12–15).